Adlai Nortye Group (ANL) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Zevra Therapeutics (ZVRA) over the past year, gaining 533.3% versus a gain of 1.9%. Adlai Nortye Group is the larger company by market cap ($550.6 million vs $521.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | ZVRA |
|---|---|---|
| Share price | $8.55 | $8.76 |
| Market cap | $550.60M | $521.26M |
| 1-day change | -5.63% | -3.42% |
| YTD return | +502.11% | -2.23% |
| 1-year return | +533.33% | +1.86% |
| 5-year return | — | +8.82% |
| P/E ratio (TTM) | — | 7.18 |
| Forward P/E | — | 9.84 |
| EPS (TTM) | $-0.66 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $106.47M |
| Revenue growth (YoY) | — | +350.91% |
| Net income (latest FY) | $-51.87M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | — | -59.12% |
| Net margin | — | 78.17% |
| 52-week high | $17.25 | $15.04 |
| 52-week low | $0.879 | $8.01 |
| Distance from 52-week high | -50.43% | -41.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +245.03% | +162.56% |
| Average volume | 244.74K | 954.53K |
| Shares outstanding | 58.73M | 59.50M |
| Employees | 109 | 61 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed ZVRA by 531.5 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees
ANL vs ZVRA FAQ
Which is bigger, Adlai Nortye Group or Zevra Therapeutics?
Adlai Nortye Group (ANL) is larger, with a market capitalization of $550.60M compared with $521.26M for Zevra Therapeutics (ZVRA).
Which stock has performed better over the past year, ANL or ZVRA?
ANL returned +533.33% over the past 12 months, compared with +1.86% for ZVRA (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.